KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.
A KAUST Rapid Research Response Team (R3T) is collaborating with healthcare stakeholders to combat COVID-19. Xin Gao and his Structural and Functional Bioinformatics (SFB) Group are developing an AI-based diagnosis pipeline from CT scans of COVID-19 patients. The AI pipeline aims to address the high false negative rates associated with nucleic acid detection. Why it matters: This research could improve COVID-19 diagnostics and potentially inform understanding of viral pathogenesis.
KAUST is offering access to its Shaheen II supercomputer and other computing resources for COVID-19 research projects by researchers across the Kingdom. Researchers can apply for computing allocations by submitting a proposal to [email protected]. The resources available include Shaheen II, the Ibex cluster, and support from KSL staff scientists. Why it matters: This initiative will accelerate COVID-19 research in Saudi Arabia by providing access to advanced computing infrastructure and expertise.
KAUST's president addressed the community regarding the university's response to COVID-19 since January, detailing the formation of a Coronavirus Task Force and Crisis Management Team. The university has issued 25 announcements, and the Saudi government's response was lauded. KAUST is balancing community health protection and minimizing disruptions with no confirmed cases at KAUST. Why it matters: This address highlights the proactive measures taken by a leading Saudi institution to manage a global health crisis, reflecting the Kingdom's broader efforts and KAUST's commitment to its community's well-being.
KAUST reflects on its COVID-19 response, highlighting community efforts, research contributions, and partnerships. Faculty are leveraging expertise in diagnostics, AI therapeutics, genomics, and epidemiology. KAUST is collaborating with the Saudi CDC, Ministry of Health, and other institutions. Why it matters: This demonstrates KAUST's role as a hub for research and innovation, contributing to both national and global health challenges during a crisis.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
An article from KAUST discusses the impact of COVID-19 on automation, material science, and VR. It suggests increased automation, voice activation, and motion detection to reduce transmission in public spaces. KAUST faculty member Derya Baran is working on antimicrobial materials for high-touch locations, and KAUST is exploring VR for virtual labs. Why it matters: The pandemic is accelerating the adoption of AI-driven solutions and advanced materials research within Saudi Arabia to address public health challenges.
KAUST is joining universities worldwide to expedite licensing for COVID-19 related technologies. KAUST researchers are focusing on developing rapid diagnostic platforms, genomic analyses, and tools to track the virus's spread, collaborating with Saudi healthcare stakeholders. By signing the AUTM COVID-19 Licensing Guidelines and adopting the COVID-19 Technology Development Framework, KAUST will offer royalty-free, time-limited, non-exclusive licenses during and after the pandemic. Why it matters: This initiative facilitates quicker development and broader access to essential technologies for combating COVID-19 in Saudi Arabia and the Middle East.